Quest Signs License Agreement With Pathway Diagnostics
Posted on: Monday, 29 October 2007, 12:00 CDT
Quest Diagnostics has entered into a non-exclusive license agreement for the heteroduplex tracking technology underlying Pathway Diagnostics's SensiTrop HIV co-receptor tropism test.
Pathway's SensiTrop technology is designed to enable physicians to identify the HIV co-receptor tropism status of a patient infected with HIV, the virus that causes AIDS.
Pathway's technology detects the CXCR4 HIV co-receptor in patient samples that have as little as 1% CXCR4-tropic virus, enabling physicians to identify with a high degree of accuracy those patients with X4-tropic virus who are unlikely to benefit from, and should not receive, treatment with entry inhibitor therapies. The heteroduplex tracking technology, which is molecular based, also can yield test results within seven days of receiving a specimen, compared to up to four weeks to receive results with cellular-based methods.
During the first quarter of 2008, Quest Diagnostics expects to develop an in-house laboratory validated assay based on the licensed technology. Until then and beginning November 1, 2007, physicians may order SensiTrop through Quest Diagnostics, which will refer the test to Pathway Diagnostics.
Walter Narajowski, CEO of Pathway Diagnostics, said: "Offering a molecular-based HIV co-receptor tropism assay through Quest Diagnostics will give the greatest number of patients the opportunity to take advantage of Selzentry and future drug therapies in its class."
Source: Datamonitor
Related Articles
- Quest Diagnostics Finalizes Previously Announced Settlement With Government Related to Test Kit Subsidiary Closed in 2006
- Pathway Diagnostics Announces Commercial Availability of Second Generation SensiTrop(TM) II Molecular HIV Co-Receptor Tropism Assay
- Adventrx's HIV Drug Exhibits Unique Resistance Profile in Preclinical Tests
- Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference Sets New Standards of Assay Sensitivity
- Roche Diagnostics' HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
- Quest Diagnostics Licenses Technology Underlying SensiTrop(TM) HIV Co-Receptor Tropism Test From Pathway Diagnostics
- Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-Receptor Tropism Assay
- Four Studies Affirm Significance of Monogram's Trofile(TM) HIV Co-Receptor Tropism Assay
- Pfizer and Monogram to Make HIV Co-Receptor Tropism Assay Available Globally
- New Research Shows Manufacturers Need to Increase Physician Awareness of Specifically Testing for Cognitive Impairment During or Soon After the Initial Diagnosis Schizophrenia, in Order to Maximize Long-Term Cis Drug Revenues
 |
 |
User Comments (0)
RSS Feeds